Daptomycin nonsusceptible enterococci in hematologic malignancy and hematopoietic stem cell transplant patients: An emerging threat

摘要

Multidrug-resistant bacterial infection is one of the major morbidity and mortality causes in hematologic malignancy and stem cell transplant (SCT) patients. Vancomycin-resistant enterococci (VRE) have been an ongoing concern in these patients. Incidence of VRE has been reported up to 30 % [1, 2]. Alternative antibiotic options include linezolid, quinupristin-dalfopristin, tigecycline, or daptomycin [3]. Daptomycin is commonly used for VRE treatment in these patients due to its tolerable side-effect profile. Over the past several years, several cases of daptomycin nonsusceptible enterococci (DNSE) have been reported [4]. Although the incidence remains relatively uncommon (<1 %), the number of DNSE becomes increasingly reported [4]. Sader et al. demonstrated that 0.3 % of vancomycin-resistant Enterococcus faecium were DNSE [5]. Kamboj et al.